Feature | November 08, 2012

FDA Develops Regulations for Intra-aortic Balloon Pumps 40 Years After Their Introduction

Panel will also discuss other cardiovascular technologies grandfathered after tightened restrictions implemented in 1979

FDA Intra-Aortic Balloon Pumps

November 8, 2012 — A U.S. Food and Drug Administration (FDA) advisory committee is meeting Dec. 5 to discuss how to classify and regulate intra-aortic balloon pumps (IABPs), which have been grandfathered without clear policy since the FDA tightened regulations on medical devices in the late 1970s. The panel will also discuss classifications for two other grandfathered technologies, including external counter-pulsating (ECP) devices and cardiopulmonary bypass blood pumps.

The meeting will be held Dec. 5 and 6 from 8 a.m. to 6 p.m. at the Holiday Inn, Gaithersburg, Md.

On Dec. 5, the Circulatory System Devices Panel of the Medical Devices Advisory Committee will discuss making recommendations regarding regulatory classification of IABPs to either reconfirm to class III (subject to premarket approval application [PMA]) or reclassify to class I or class II (subject to premarket notification [510(k)]). IABPs and their control systems are one of the remaining pre-amendment class III devices.

In 1979, the FDA published a proposed rule for classification of IABP devices as class III requiring PMA. The panel recommended class III because the device is life supporting and because the panel believed that insufficient medical and scientific information existed to establish a standard to assure the safety and effectiveness of the device. The panel also stated that controversy exists as to whether the device is beneficial in the many situations in which it is used, and that it is difficult to use the device safely and effectively.

Subsequent to the proposed rule, in 1980, the FDA classified IABP devices into class III after receiving no comments on the proposed rule. In 1987, FDA published a clarification by inserting language in the codified language, stating that no effective date had been established for the requirement for premarket approval for IABP devices.

On Dec. 5, the committee will also discuss external counter-pulsating (ECP) devices. These systems typically consist of a treatment table, pressure cuffs and a controller. They are intended to provide noninvasive circulatory support by applying external pressure to the lower extremities during diastole to increase coronary perfusion pressure, and releasing external pressure during systole to reduce left ventricular workload.  

On Dec. 6, the committee will discuss nonroller-type cardiopulmonary bypass blood pumps, another remaining pre-amendment class III device. These devices use a method other than revolving rollers to pump blood. The FDA has reviewed two types: Centrifugal type pumps utilize a rotor to impart energy to the blood in an extracorporeal circuit through centrifugal forces. These pumps are part of an extracorporeal circuit usually containing an oxygenator and are intended to provide cardiopulmonary support, during procedures such as cardiopulmonary bypass surgery, for periods lasting six hours or less. Micro-axial type pumps are comprised of a pump motor, a cannula and a catheter that connects to a console. These pumps are not designed to be used with an oxygenator but are temporarily placed within the heart or vasculature to provide cardiac support only.    

FDA intends to make background material available to the public no later than two business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's website after the meeting.

For more information: www.fda.gov/AdvisoryCommittees/default.htm

Related Content

tryton side branch stent, bifurcation stenting, Cardinal Health
News | Stents Bifurcation| October 28, 2016
October 28, 2016 – Tryton Medical Inc., a primary developer of stents to treat coronary bifurcation lesions, and Card
Aggrastat Bolus Vial, IV antiplatelet agent
Technology | Antiplatelet and Anticoagulation Therapies| October 28, 2016
October 28, 2016 — Medicure Inc. recently received U.S.
PCI, operator volume, China study, JACC, outcomes
News | Cath Lab| October 27, 2016
Volume matters when it comes to who does certain procedures to removing heart-attack causing blockages from arteries,...
Corindus, Corpath, robotic navigation, Robotic PCI, CorPath GRX
Technology | October 27, 2016
October 27, 2016 — Corindus Vascular Robotics Inc. announced it received 510(k) clearance from the U.S.
Interventional cardiology, cath lab technology, TCT, transcatheter cardiovascular therapeutics
Feature | Cath Lab| October 27, 2016 | Dave Fornell
The volume of information attendees receive at the annual Transcatheter Cardiovascular Therapeutics (TCT) interventio
Philips, TCT 2016, image guidance technologies, iFR, HeartNavigator
News | Cath Lab| October 26, 2016
Philips recently announced its latest image guidance solutions to be featured at the 2016 Transcatheter Cardiovascular...
Medtronic, CoreValve Evolut R, TAVR system, 34 mm valve, FDA approval, largest in the U.S.
Technology | Heart Valve Technology| October 26, 2016
Medtronic announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the CoreValve Evolut R 34...
medicare bundled cardiac payments, CMS cardiology payments
Feature | Business| October 24, 2016 | By John W. Meyer, MPH, FACHE
(Editor’s note: This is the second part of a two-part series on the proposed Medicare five-year demonstration for
Overlay Init